6.23
price up icon3.99%   0.22
after-market Handel nachbörslich: 6.12 -0.11 -1.77%
loading
Schlusskurs vom Vortag:
$6.01
Offen:
$5.85
24-Stunden-Volumen:
613.50K
Relative Volume:
0.52
Marktkapitalisierung:
$485.12M
Einnahmen:
$14.79M
Nettoeinkommen (Verlust:
$-102.44M
KGV:
-2.0493
EPS:
-3.04
Netto-Cashflow:
$-91.73M
1W Leistung:
+13.22%
1M Leistung:
+15.96%
6M Leistung:
+130.63%
1J Leistung:
+2.29%
1-Tages-Spanne:
Value
$5.81
$6.28
1-Wochen-Bereich:
Value
$5.535
$6.79
52-Wochen-Spanne:
Value
$2.41
$7.37

Solid Biosciences Inc Stock (SLDB) Company Profile

Name
Firmenname
Solid Biosciences Inc
Name
Telefon
617-337-4680
Name
Adresse
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Name
Mitarbeiter
100
Name
Twitter
@SolidBioDMD
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
SLDB's Discussions on Twitter

Vergleichen Sie SLDB mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
SLDB
Solid Biosciences Inc
6.23 467.99M 14.79M -102.44M -91.73M -3.04
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
412.22 104.45B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
469.36 60.95B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.60 59.11B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
812.95 49.23B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
320.94 35.92B 4.56B -176.77M 225.30M -1.7177

Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-26 Eingeleitet Citigroup Buy
2025-01-08 Eingeleitet Truist Buy
2024-12-13 Eingeleitet Wedbush Outperform
2024-12-10 Eingeleitet JMP Securities Mkt Outperform
2024-07-15 Hochstufung JP Morgan Neutral → Overweight
2024-06-24 Hochstufung Leerink Partners Market Perform → Outperform
2024-05-31 Fortgesetzt Piper Sandler Overweight
2024-03-28 Eingeleitet William Blair Outperform
2024-03-15 Eingeleitet Citigroup Buy
2024-03-14 Hochstufung Piper Sandler Neutral → Overweight
2023-12-08 Eingeleitet H.C. Wainwright Buy
2021-07-12 Eingeleitet Piper Sandler Neutral
2021-05-27 Eingeleitet Jefferies Buy
2021-03-16 Hochstufung SVB Leerink Mkt Perform → Outperform
2021-03-09 Eingeleitet Barclays Overweight
2021-01-08 Hochstufung Credit Suisse Underperform → Neutral
2020-07-28 Herabstufung SVB Leerink Outperform → Mkt Perform
2020-05-07 Herabstufung Evercore ISI Outperform → In-line
2019-10-11 Eingeleitet Evercore ISI Outperform
2019-08-29 Herabstufung Citigroup Neutral → Sell
2019-08-19 Hochstufung SVB Leerink Mkt Perform → Outperform
2019-08-16 Hochstufung Chardan Capital Markets Neutral → Buy
2019-05-14 Herabstufung Credit Suisse Neutral → Underperform
2019-05-14 Herabstufung Goldman Neutral → Sell
2019-02-08 Hochstufung Citigroup Sell → Neutral
2019-02-08 Herabstufung SVB Leerink Outperform → Mkt Perform
2018-11-06 Eingeleitet Citigroup Sell
2018-09-06 Eingeleitet Credit Suisse Neutral
Alle ansehen

Solid Biosciences Inc Aktie (SLDB) Neueste Nachrichten

pulisher
04:25 AM

Why Solid Biosciences Inc. stock is favored by pension fundsEarnings Miss & High Conviction Buy Zone Alerts - newser.com

04:25 AM
pulisher
Oct 13, 2025

How sustainable is Solid Biosciences Inc. stock dividend payoutMarket Trend Report & Free Technical Confirmation Trade Alerts - newser.com

Oct 13, 2025
pulisher
Oct 13, 2025

How to monitor Solid Biosciences Inc. with trend dashboards2025 Volume Leaders & AI Forecasted Entry and Exit Points - newser.com

Oct 13, 2025
pulisher
Oct 13, 2025

Volume spikes in Solid Biosciences Inc. stock – what they meanJuly 2025 Rallies & AI Driven Stock Reports - newser.com

Oct 13, 2025
pulisher
Oct 13, 2025

Is Solid Biosciences Inc. stock in correction or buying zoneMarket Activity Report & Safe Investment Capital Preservation Plans - newser.com

Oct 13, 2025
pulisher
Oct 13, 2025

Is Solid Biosciences Inc. stock positioned for long term growth2025 Stock Rankings & Community Trade Idea Sharing Platform - newser.com

Oct 13, 2025
pulisher
Oct 13, 2025

Why Solid Biosciences Inc. stock is trending among retail tradersJuly 2025 Chart Watch & Advanced Swing Trade Entry Alerts - newser.com

Oct 13, 2025
pulisher
Oct 12, 2025

Using portfolio simulators with Solid Biosciences Inc. includedWeekly Investment Report & Growth Oriented Trading Recommendations - newser.com

Oct 12, 2025
pulisher
Oct 12, 2025

Price momentum metrics for Solid Biosciences Inc. explainedQuarterly Trade Summary & Capital Efficiency Focused Ideas - newser.com

Oct 12, 2025
pulisher
Oct 11, 2025

Is Solid Biosciences Inc. stock ready for a breakoutTrade Volume Report & Daily Technical Stock Forecast Reports - newser.com

Oct 11, 2025
pulisher
Oct 11, 2025

Solid Biosciences (NASDAQ:SLDB) Upgraded at Wall Street Zen - MarketBeat

Oct 11, 2025
pulisher
Oct 09, 2025

Visual trend scoring systems applied to Solid Biosciences Inc.Layoff News & Accurate Intraday Trading Signals - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Duchenne Muscular Dystrophy Drugs Market Global Forecast - GlobeNewswire

Oct 09, 2025
pulisher
Oct 09, 2025

Duchenne Muscular Dystrophy Drugs Market Global Forecast 2025-2032: Sarepta, Pfizer, BioMarin, Roche, Bayer, Solid Biosciences, Cytokinetics, and NS Pharma Drive Innovation and Commercial Expansion - Yahoo Finance

Oct 09, 2025
pulisher
Oct 09, 2025

Solid Biosciences (NASDAQ:SLDB) Receives "Sell (D-)" Rating from Weiss Ratings - MarketBeat

Oct 09, 2025
pulisher
Oct 09, 2025

Will Solid Biosciences Inc. stock attract ESG investors2025 Earnings Impact & Real-Time Volume Analysis Alerts - newser.com

Oct 09, 2025
pulisher
Oct 08, 2025

Solid Biosciences (NASDAQ:SLDB) Trading 22% HigherTime to Buy? - MarketBeat

Oct 08, 2025
pulisher
Oct 06, 2025

Solid Biosciences Raises up to $50 Million in Series C Financing - Bain Capital

Oct 06, 2025
pulisher
Oct 05, 2025

Can Solid Biosciences Inc. stock deliver sustainable ROE2025 Earnings Impact & High Accuracy Investment Signals - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Trend analysis for Solid Biosciences Inc. this weekForecast Cut & Free Weekly Chart Analysis and Trade Guides - newser.com

Oct 05, 2025
pulisher
Oct 02, 2025

Is Solid Biosciences Inc. forming a bottoming baseMarket Trend Report & AI Optimized Trading Strategy Guides - newser.com

Oct 02, 2025
pulisher
Oct 01, 2025

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Oct 01, 2025
pulisher
Oct 01, 2025

Solid Biosciences to Present at Upcoming Scientific Meetings - GlobeNewswire

Oct 01, 2025
pulisher
Oct 01, 2025

Next-Gen Duchenne Muscular Dystrophy Treatment Update: Solid Bio's Gene Therapy Trial Results Coming - Stock Titan

Oct 01, 2025
pulisher
Sep 30, 2025

Electrovaya Inc Stock Analysis and ForecastDividend Stability Analysis & Stay Invested. Stay Smart. - earlytimes.in

Sep 30, 2025
pulisher
Sep 30, 2025

Solid Biosciences Inc. stock volume spike explainedMarket Performance Summary & Consistent Profit Focused Trading Strategies - newser.com

Sep 30, 2025
pulisher
Sep 29, 2025

Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Recommendation of "Buy" by Brokerages - MarketBeat

Sep 29, 2025

Finanzdaten der Solid Biosciences Inc-Aktie (SLDB)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Solid Biosciences Inc-Aktie (SLDB) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Bain Capital Life Sciences Inv
10% Owner
Feb 19 '25
Buy
4.03
1,000,000
4,030,000
5,034,582
PERCEPTIVE ADVISORS LLC
Director
Feb 19 '25
Buy
4.03
5,000,000
20,150,000
11,833,539
Adage Capital Management, L.P.
10% Owner
Feb 18 '25
Buy
7.56
252,545
1,909,240
4,248,084
Hanrahan Jessie
Chief Regulatory Officer
Feb 14 '25
Sale
3.96
3,079
12,193
19,281
Brooks Gabriel
Chief Medical Officer
Feb 14 '25
Sale
3.96
3,256
12,894
22,812
Tan Kevin
CFO & Treasurer
Feb 14 '25
Sale
3.96
3,164
12,529
32,250
Howton David T
Chief Operating Officer
Feb 14 '25
Sale
3.96
5,561
22,022
24,789
Herzich Paul
Chief Technology Officer
Feb 14 '25
Sale
3.96
2,688
10,644
18,388
Cumbo Alexander
President and CEO
Feb 14 '25
Sale
3.96
11,365
45,005
60,717
Ganot Ilan
Director
Feb 14 '25
Sale
3.96
1,711
6,776
14,839
$21.75
price down icon 5.47%
$85.96
price up icon 1.59%
$32.75
price up icon 0.41%
$102.61
price up icon 0.29%
$161.38
price down icon 1.45%
biotechnology ONC
$320.94
price down icon 1.85%
Kapitalisierung:     |  Volumen (24h):